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Abstract
Gangliosides are sialic acid-containing glycolipids expressed on plasma membranes from nearly all vertebrate cells. The
expression of ganglioside GD3, which plays essential roles in normal brain development, decreases in adults but is up
regulated in neuroectodermal and epithelial derived cancers. R24 antibody, directed against ganglioside GD3, is a validated
tumor target which is specifically endocytosed and accumulated in endosomes. Here, we exploit the internalization feature
of the R24 antibody for the selective delivery of saporin, a ribosome-inactivating protein, to GD3-expressing cells [human
(SK-Mel-28) and mouse (B16) melanoma cells and Chinese hamster ovary (CHO)-K1 cells]. This immunotoxin showed
a specific cytotoxicity on tumor cells grew on 2D monolayers, which was further evident by the lack of any effect on GD3-
negative cells. To estimate the potential antitumor activity of R24-saporin complex, we also evaluated the effect of the
immunotoxin on the clonogenic growth of SK-Mel-28 and CHO-K1GD3+ cells cultured in attachment-free conditions. A
drastic growth inhibition (.80–90%) of the cell colonies was reached after 3 days of immunotoxin treatment. By the
contrary, colonies continue to growth at the same concentration of the immuntoxin, but in the absence of R24 antibody, or
in the absence of both immunotoxin and R24, undoubtedly indicating the specificity of the effect observed. Thus, the
ganglioside GD3 emerge as a novel and attractive class of cell surface molecule for targeted delivery of cytotoxic agents
and, therefore, provides a rationale for future therapeutic intervention in cancer.
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Introduction
Gangliosides are a heterogeneous family of sialic acid-contain-
ing glycosphingolipids present on plasma membranes, where they
participate in cell-surface events such as modulation of growth
factor receptors and cell-to-cell and cell-to matrix interactions [1].
Aberrant glycosilation occurs in essentially all types of experimen-
tal and human cancers, and many glycosil epitopes constitute
tumor-associated antigens [2]. The expression of non-normal
glycosil epitopes is believed to affect tumor progression, promoting
or inhibiting it [2]. Malignant transformation of cells, especially
those of neuroectodermal origin (like melanoma and neuroblas-
toma), often result in elevated expression of gangliosides such us
GM2, GD2, GD3 and 9-O-acetyl-GD3 [3,4].
Antibody-based cancer immunotherapies use antibody depen-
dent cellular cytotoxicity and complement-dependent cytotoxicity,
or enhance natural effects of antibodies by arming these with
radioisotopes, toxins or drugs. Thus, several types of targeted
therapy need that the antibody remains at the cell surface to
mediate cytotoxicity, but other therapies need internalization and
drug release into the cell [5]. Anti-ganglioside antibodies are
available, like anti-GD2 for neuroblastoma [6] and anti-GD3 for
melanoma [7]. Particularly, mouse monoclonal R24 antibody
(IgG3), directed against ganglioside GD3, is a validated tumor
targeting agent that shows strong cell surface reactivity with
a range of human melanoma cell lines and other epithelial cancer
tumor cells [7].
In a previous study, we demonstrated that the R24 antibody is
rapidly endocytosed after binding to the disialo ganglioside GD3,
sorted to early endosomes, latter accumulated in the recycling
endosome and finally transported back to the plasma membrane
[8]. Its rapid internalization in cells precludes its use as a ‘‘naked’’
therapeutic because when internalized it cannot link to pathways
of complement- and cellular- dependent anticancer activity.
However, it would be possible to exploit the internalization
feature for the selective delivery of cytotoxic agents to GD3-
expressing cancer cells. In this study, we take advantage of the
internalization feature of R24 antibody for selective delivery of
saporin, a ribosome-inactivating protein, to GD3-expressing cells.
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Figure 1. R24 antibody is specifically internalized in GD3-expressing cells. A) CHO-K1GD3+, CHO-K1WT (GD3-) and SK-Mel-28 cells grown on
coverslips were incubated at 4uC to inhibit intracellular transport, then with R24 antibody for 45 min at 4uC, washed and fixed. R24 antibody was
detected by using goat anti-mouse IgG conjugated with Alexa Fluor488 (45 min, 4uC; left panels). B) Cells were incubated with R24 for 45 min at 4uC
and after washing temperature was shifted to 37uC for 30 min to allow the endocytosis of the complex GD3-R24. Then, cells were fixed and R24
antibody detection was carried out as indicated in A (30 min, 37uC; right panel). Single confocal sections were taken every 0.8 mm parallel to the
coverslip. The fluorescence micrographs shown are representative of three independent experiments. Scale bar: 10 mm.
doi:10.1371/journal.pone.0055304.g001
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First, the ablation cell strategy was successfully established in
Chinese hamster ovary (CHO)-K1 cells and latter demonstrated to
be effective both in human (SK-Mel-28) and mouse (B16)
melanoma cells. We propose that chemical coupling of antibodies
to gangliosides with chemotherapeutics would allow the in-
tracellular delivery of cytotoxic agents and, therefore, provides
a rationale for future therapeutic intervention in cancer.
Materials and Methods
Inhibition of In Vitro Cell Proliferation
The following cells were used: wild-type CHO-K1 (CHO-K1wt)
cells (ATCC, Manassas, VA, USA); CHO-K1 clone 2 (CHO-
K1GD3+), a stable CMP-NeuAc:GM3a2,8-sialyltransferase (Sial-
T2, tagged at the C-terminus with the nanopeptide epı´tope of the
viral hemagglutinin) transfectant expressing the ganglioside GD3
[9,10]; and the SK-Mel 28 and B16 melanoma cell lines (ATCC).
Cells were grown and maintained at 37uC in 5% CO2 in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and antibiotics. 4500–5000 cells
were cultured at 37uC in 96-well plates at the indicated
concentration of monoclonal antibody to GD3 (R24 antibody,
hybridoma ATCC Nu HB-8445) plus goat antibody to mouse IgG
or saporin conjugated goat antibody anti mouse IgG secondary
antibody (Advance Targeting Systems, San Diego, CA, USA). R24
and secondary antibody complexes were first incubated in an
eppendorf and then incorporated into the culture medium. Cell
viability was monitored at 72 h employing 3-(4,5 dimethylthiazol-
2-yl)-2,5 diphenyltetrazolium bromide (MTT) metabolic reduc-
tion. Absorbance was measured at 595 nm using a multiplate
reader. Results were analyzed by ANOVA followed by Tukey’s
multiple comparison test to determine if significant differences
existed between groups (p,0.05). Results are given as means6S.E.
Generation of Stably Transfected Mouse B16 Melanoma
Cell Clone Expressing Sial-T2
Wild-type B16 mouse melanoma cells (B16wt) grown in DMEM
medium-10% FBS at 37uC in 5% CO2 were transfected with
1 mg/dish pCEFL-Sial-T2-HA using Lipofectamine (Invitrogen,
Carlsbad, CA, USA) [10]. After 24 h of expression, the cells were
cultured in DMEM containing 10% FBS and 1 mg/ml geneticin
(G418). Colonies of stable transfectants were screened for GD3
ganglioside expression and GD3-positive cells were isolated by cell
sorter procedure. B16GD3+ cells were maintained in 0.5 mg/ml
G418.
Soft Agar Colony Assay
This method was carried out essentially as described [11]. 24-
well plates were coated with 0.3 ml of 0.5% agar (Sigma-Aldrich,
St. Louis, MO, USA) in DMEM supplemented with 20% FBS.
For each dish, 50–100 cells were suspended in 0.3 ml medium
with 20% FBS, mixed with 1 ml of 0.375% soft agar in DMEM
containing 20% FBS, and dispensed into the well plates. Cells
were incubated at 37uC in a hummed atmosphere of 5% CO2
until cell colonies appeared.
Cell Labeling and Internalization Assays
Cells grown on coverslips were incubated on ice for 20 min to
inhibit intracellular transport. Then, cells were incubated on ice
for 45 min with R24 antibody (1:100 dilution) in order to label
GD3 ganglioside expressed on the cell surface. Afterwards, cells
Figure 2. Selective cytotoxicity of R24-targeted immunotoxin
on epithelial and melanoma cells. CHO-K1WT (GD32) (A), CHO-
K1GD3+ (B) and SK-Mel-28 (C) cells were cultured at 37uC for 72 h in 96-
well plates and treated with the indicated concentration of monoclonal
antibody to GD3 (R24 antibody) in combination with secondary
antibody: goat antibody to mouse IgG (squares, black lines) or saporin
conjugated goat antibody to mouse IgG (circles, grey lines). As negative
control (100% viability), CHO-K1WT, CHO-K1GD3+ and SK-Mel-28 cells
were incubated only with culture medium. The concentration of the
secondary antibodies was as follows: 0.95 nM for CHO-K1wt and CHO-
K1GD3+ and 9.5 nM for SK-Mel-28. Cell viability was determined using
the colorimetric MTT metabolic activity assay. Absorbance was
measured at 595 nm using a multiplate reader. Results were analyzed
by ANOVA followed by Tukey’s multiple comparison test. Results are
given as means6S.E. The relative cell viability (%) was expressed as
a percentage relative to the untreated control cells. Note that R24-
targeted saporin selectively kill epithelial and melanoma cells
(**p,0.001, respect to control condition). CHO-K1GD3+ (clone 2) shows
some cell-to-cell variability in the expression of GD3 in non-
synchronized cultures, which is more evident after several passages.
The differences in GD3 expression levels could contribute to the
variability of the observations on cells exposed to R24/Saporin-Ab.
doi:10.1371/journal.pone.0055304.g002
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Figure 3. Selective cytotoxicity of R24-targeted immunotoxin on mouse B16GD3+ melanoma cells. A) Wild-type B16 cells (B16wt) and B16
cells genetically modified to express GD3 (B16GD3+) grown on coverslips were incubated at 4uC to inhibit intracellular transport, then with R24
antibody for 45 min at 4uC, washed and fixed. R24 antibody was detected by using anti-mouse IgG conjugated with Alexa Fluor488 (45 min, 4uC; left
Ganglioside GD3-Targeted Immunotoxin
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were washed three times with cold PBS, transferred to 37uC with
fresh prewarmed complete DMEM to allow antibody internaliza-
tion for 30 min and finally fixed in 4% paraformaldehyde in PBS
for 20 min at 4uC. Then, cells were washed twice with PBS and
permeabilized with 0.1% Triton X-100/200 mM glycine in PBS
for 10 min. Next, cells were washed with PBS and exposed to
secondary antibody for 90 min at 37uC. Secondary antibody was
Alexa Fluor488-conjugated goat anti-mouse IgG (Molecular
Probes, Eugene, OR, USA) diluted 1:1000. After final washes
with PBS, cells were mounted in FluorSave reagent (Calbiochem,
EMD Biosciences, La Jolla, CA, USA).
Confocal Immunofluorescence Microscopy
Confocal images were collected using a Carl Zeiss LSM5 Pascal
laser-scanning confocal microscope (Carl Zeiss, Jena, Germany)
equipped with an argon/helium/neon laser and a 6361.4
numerical aperture, oil immersion objective (Zeiss Plan-Apochro-
mat) or with an Olympus FluoViewTM FV1000 confocal
microscope equipped with an argon/helium/neon laser and
a 6361.42 numerical aperture, oil immersion objective. Single
confocal sections of 0.7 mm were taken parallel to the coverslip (xy
sections). Images were acquired and processed with the Zeiss LSM
image software or Olympus FluoView FV10-ASW software. Final
images were compiled with Adobe Photoshop CS. The fluores-
cence micrographs shown in this manuscript are representative of
at least three independent experiments.
Results
Binding and Specific Internalization of R24 Antibody in
GD3-Expressing Cells
Parental CHO-K1 cells only express the ganglioside GM3.
CHO-K1 cells stably transfected with the cDNA encoding Sial-T2
(clone 2, CHO-K1GD3+ cells) synthesize mostly GD3 [9,10]. As
shown in Figure 1, binding of R24 antibody to live CHO-K1GD3+
cells at 4uC had a plasma membrane punctate distribution. After
30 min at 37uC, the internalized R24 antibody became more
concentrated in the perinuclear region, which was previously
identified as recycling endosomes [8]. Similar binding and
internalization of R24 antibody bound to GD3 was also observed
in human SK-Mel-28 melanoma cells, which mainly express the
ganglioside GD3 and GM3 (Fig. 1). Endocytosis of R24 is
specifically mediated by GD3, as wild-type CHO-K1 cells did not
bind and internalize R24 (Fig. 1). Thus, the ganglioside GD3
become an attractive cell surface molecule to be targeted in
antibody-mediated intracellular delivery of cytotoxic agents in
GD3-expressing tumor cells.
R24-Targeted Immunotoxin Shows Specific Cytotoxicity
on Epithelial and Melanoma Cells
To evaluate the possibility mentioned in the last paragraph, we
tested whether the antibody to GD3 is able to selectively deliver
the toxin saporin into GD3-expressing cells. As a first approach,
we used a dual system in which a secondary antibody coupled to
saporin is bound to the mouse antibody to GD3 R24. We
demonstrated that the intracellular fate and timing of internali-
zation of both R24 and R24-saporin-Ab complex are essentially
the same (Figure S1). Initial titration of the R24/Saporin-Ab at 1:1
molar ratio in CHO-K1GD3+ indicated that an R24 concentration
of 3 pM was sufficient for initial testing the ability of antibody R24
to deliver saporin into the cells and to induce cell death in a time-
dependent process (results not shown). In order to determinate the
optimum ratio of Saporin-Ab to the anti GD3 monoclonal
antibody (R24) in CHO-K1GD3+ cells, the concentration of the
secondary antibody-saporin was maintained at 0.95 nM and the
primary antibody was varied from 0.003 pM to 20 nM. After 72 h
of incubation with R24 at 20 nM, more than 50% of CHO-K1
cells stably expressing GD3 were killed (Fig. 2B). We discard the
possibility of selection of GD3 negative cells after 72 h of saporin
exposure since the expression GD3 in residual cells was similar to
that observed in control cells (Figure S2). As also indicated in
Figure 2B, primary antibody R24 in the absence of Saporin-Ab
had no a significant effect (,10%) on cell growth. In addition, the
complex consisting of control IgG (mouse IgG anti c-Myc) and
Saporin-Ab had no effect even after 72 h of treatment (results nor
shown). The specificity of R24 antibody for delivering saporin was
also determined using wild-type CHO-K1 cells which do not
express GD3 and express only GM3 (Fig. 2A). Clearly, this cell line
was not affected under the identical culture conditions, even at
higher doses of R24 antibody.
Next, we attempted to evaluate the effect of R24-mediated
intracellular delivery of saporin in human SK-Mel-28 melanoma
cells, which endogenously express the ganglioside GD3 [8]. As
observed in CHO-K1GD3+ cells, R24/Saporin-Ab complex killed
between 25 and 33% of the cells at 60–90 nM of the primary
antibody incubated with 9.5 nM Saporin-Ab (Fig. 2C). Then, we
evaluated cytotoxicity of immunotoxin on B16 melanoma cells
(GM3+) genetically modified to express the ganglioside GD3 by
stable transfection with Sial-T2. The expression of GD3 was
clearly observed at the plasma membrane of live cells a 4uC, which
was latter endocytosed by changing the temperature to 37uC
(Fig. 3A). In contraposition to CHO-K1GD3+ and SK-Mel-28 cells,
GD3-R24 did not significantly colocalyze with coendocytosed
transferrin in experimental conditions set up to label recycling
endosomes (30 min of uptake at 37uC). However, we observed
extensive colocalization with Rab5 (early endosome marker) and
panels). Cells were incubated with R24 for 45 min at 4uC and after washing temperature was shifted to 37uC for 30 min to allow the endocytosis of
the complex GD3-R24. Then, cells were fixed and R24 antibody detection was carried out as indicated above (30 min, 37uC; right panels). B) B16GD3+
cells transiently expressing Rab5-GFP or Lamp1-GFP were incubated with R24 for 45 min at 4uC. After washing, temperature was shifted to 37uC for
30 min to allow the endocytosis of the complex GD3-R24. R24 antibody was detected by using anti-mouse IgG conjugated with Alexa Fluor543.
Expression of Rab5 and Lamp1 was detected by the intrinsic fluorescence of GFP. In another set of experiments, uptake of Alexa Fluor647-transferrin
(Tf) was monitored simultaneously with R24 endocytosis. In this case, R24 antibody was detected by using anti-mouse IgG conjugated with Alexa
Fluor488. Insets in merge panels (right column) show details at higher magnifications. In all experimental conditions, single confocal sections were
taken every 0.8 mm parallel to the coverslip. The fluorescence micrographs shown are representative of three independent experiments. Scale bar:
10 mm. C) B16wt and B16GD3+ cells were cultured at 37uC for 72 h in 96-well plates at the indicated concentration of monoclonal antibody to GD3
(R24 antibody) in combination with goat antibody to mouse IgG (squares, black lines) or saporin conjugated goat antibody anti mouse IgG secondary
antibody (circles, grey lines). The concentration of the secondary antibodies was 0.95 nM. As negative control (100% viability), B16GD3+ cells were
incubated only with culture medium. Cell viability was determined using the colorimetric MTT metabolic activity assay. Absorbance was measured at
595 nm using a multiplate reader. Results were analyzed by ANOVA followed by Tukey’s multiple comparison test. Results are given as means6S.E.
The relative cell viability (%) was expressed as a percentage relative to the untreated control cells. Note that R24-targeted saporin selectively kills
B16GD3+ melanoma cells (** p,0.001, respect to control condition).
doi:10.1371/journal.pone.0055304.g003
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lysosome-associated membrane protein 1 (Lamp1) (late endosome
and lysosome marker), indicating that the R24 antibody is
probably targeted to the degradation pathway (Fig. 3B). In-
dependent of these alternative intracellular routes, we were also
able to demonstrate selective cytotoxicity of immunotoxin on
mouse B16(GD3+) melanoma cells (Fig. 3C). Taken together, our
results indicate that the ganglioside GD3 is a valid target for
antibody-mediated intracellular delivery of cytotoxic agents in
different cell types.
Selective Delivery of Toxin Via R24 Antibody Drastically
Inhibit the Clonogenic Growth of GD3-Expressing Cells
To estimate the potential antitumor activity of R24/Saporin-Ab
complex, we evaluated the effect of the immunotoxin on the
clonogenic growth of CHO-K1 cells grown on semisolid medium.
CHO-K1 cells expressing the ganglioside GD3 were grown during
7 days to allow the formation of colonies containing approximately
60–80 cells. Then, cells were exposed to 30 nM R24/0.95 nM
Saporin-Ab and the size of the colony scored at different times. As
shown in Figure 4B and C, a drastic growth inhibition of CHO-
K1GD3+ cells was reached after 3 days of immunotoxin treatment.
By the contrary, CHO-K1GD3+ colonies continue to growth at the
same concentration of the immuntoxin, but in the absence of R24
antibody, or in the absence of both immunotoxin and R24,
undoubtedly indicating the specificity of the effect observed.
Next, we investigated the effect of the immunotoxin on the
clonogenic growth of human SK-Mel-28 melanoma cell. As
observed in CHO-K1 cells, the complex R24/Saporin-Ab had
a significant and specific effect on the growing of the colonies
(Fig. 5A and B). Human SK-Mel-28 melanoma cells grown in
attachment-free conditions were more sensible to the action of
saporin than in 2D monolayer. The concentration of saporin-Ab
used for this cell line in clonogenic assays was 10-fold lower than in
the 2D monolayer experiments. Interestingly, a drastic effect of the
immunotoxin on the clonogenic growth of CHO-K1GD3+ and SK-
Mel-28 cells was also observed when the cells were treated with the
complex R24/Saporin-Ab at the moment of plating the cells in the
semisolid medium, before colony formation (Fig. 6B and C).
Taken together, these results clearly indicated that the complex
R24/Saporin-Ab exert a notable cytotoxic effect on tumor cells
grew both on 2D monolayers or cultured in attachment-free
conditions, being more evident in the last culture condition.
Discussion
The use of antibodies to specifically target different cell
populations has become an increasingly desirable method for
treatment of a variety of diseases. Cell surface receptors are main
targets for immunotherapy due to the fact that they often play
important roles in tumor biology, where they are overexpressed or
display abnormal signaling. Therapeutic strategies include the use
of i) unlabeled antibodies that kill tumor cells through induction of
apoptosis, antibody-dependent cell-mediated cytotoxicity, and/or
complement-dependent cytotoxicity; ii) radiolabeled antibodies to
induce response in patients who are resistant to unlabeled
antibodies and iii) antibody-drug conjugates, wherein a highly
potent cytotoxic agent (drugs or toxins) is directed to the tumor by
appending it to an antibody. In the last strategy, the cytotoxic
agent is released upon internalization of the antibody-drug
complex and causes the cell death.
The disialo ganglioside GD3 is a glycolipid highly expressed at
early developmental stages of the central nerve system, when
neural cells proliferate actively. At later developmental stages, the
GD3 content declines and others gangliosides become major
species [12,13]. In addition, the expression level of gangliosides in
general, and GD3 in particular, is very low and restricted in adult
extra neural tissues. However, GD3 is highly expressed in tumor
cells, accounting for more than 80% of melanomas. It is also
overexpressed in neuroectodermal tumors (neuroblastoma and
glioma) and carcinomas, including lung, breast, colon, prostate
and ovary [14]. For these reasons, ganglioside GD3 has received
considerable attention as a promising immunotherapeutic target
for cancer therapy. As such, it has been used for passive [15] and
active [16] immunotherapy of melanoma cancer. However, results
with antibody therapy are still modest and generation of new
GD3-specific chimeric antigen receptors with improved efficacy in
human primary T lymphocytes is being evaluated [14].
We demonstrated that the R24 antibody to GD3 is rapidly
endocytosed after binding to the disialo ganglioside at the cell
surface, sorted to early endosomes and latter accumulated in
recycling endosome [8]. Here, we also demonstrated in B16GD3+
melanoma cells that R24 antibody follows an alternative endocytic
route, being probably targeted to the lysosomal degradation
pathway. In this work, we exploited the internalization feature of
the R24 antibody for the selective delivery of the cytotoxic agent
saporin to GD3-expressing cells. Saporin is found in seeds and
leaves of the plant Saponaria officinales and function as an RNA N-
glycosidase and inhibits protein synthesis by cleaving one specific
adenine base from ribosomal RNA and inducing irreversible
ribosomal damage [17]. Saporin does not appear to possess
putative translocation domain(s). Thus, the precise mechanism(s)
used by saporin to reach the cytosolic compartment remains still
unclear.
We had previously demonstrated that GD3 was suitable to
mediate the intracellular delivery of R24 antibody alone or
associated with a secondary anti mouse IgG antibody-Alexa
Fluor488 [8]. Thus, we took advantage of this internalization
feature of R24 antibody for selective delivery of saporin using
a goat anti mouse IgG antibody linked to the ribosome-
inactivating toxin. The immunotoxin was found to be specifically
cytotoxic for GD3-expressing CHO-K1 and melanoma cells
grown both on 2D monolayers and cultured in attachment-free
conditions (clonogenic growth). We know that R24/saporin-Ab
complex binds GD3 at the cells surface of CHO-K1 and SK-Mel-
28 cells, being later endocytosed probably by a clathrin in-
dependent process [8]. After internalization, the immunotoxin
complex transits the endosomal compartments and accumulates
mainly in the recycling endosome, from where we speculate
Figure 4. Targeted delivery of immunotoxin by R24 antibody inhibit the clonogenic growth of CHO-K1GD3+ cells. A) A schematical
representation of the experimental procedure used in (B and C). B) CHO-K1GD3+ cells (50–80 cells) were grown in 24-well plates previously coated
with 0.5% agar in DMEM supplemented with 20% FBS. Cells were maintained at 37uC in a hummed atmosphere until cell colonies appeared (7 days,
upper row. Colonies indicated with arrows). Then, cells were treated for 3 days (7+3 days, lower row) with 0.95 nM Saporin-Ab (Saporin-Ab, middle
panel) or 30 nM R24/0.95 nM Saporin-Ab (R24/Saporin-Ab, right panel). CHO-K1GD3+ cells maintained only with medium were used as negative
control (control, left panel). The micrographs are representative of three independent experiments. C) Quantification of the colony area at 7 and 7+3
days at the different conditions indicated in B. Results were analyzed by ANOVA followed by Tukey’s multiple comparison test. Results are given as
means6S.E. Note that the clonogenic growth of CHO-K1GD3+ cells was severely affected only in presence of R24/Saporin-Ab (*** p,0.0001, respect to
control condition at 7+3 days).
doi:10.1371/journal.pone.0055304.g004
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Figure 5. Selective delivery of saporin via R24 antibody drastically reduces the clonogenic growth of human SK-Mel-28 melanoma
cells. A) SK-Mel-28 cells (50–80 cells) were grown in 24-well plates previously coated with 0.5% agar in DMEM supplemented with 20% FBS. Cells
were maintained at 37uC in a hummed atmosphere until cell colonies appeared (7 days). Then, cells were exposed for 3 days (7+3 days) to 0.95 nM
Saporin-Ab or 30 nM R24/0.95 nM Saporin-Ab. Colonies are indicated with arrows. B) Quantification of the colony area was performed at 7 and 7+3
days. SK-Mel-28 cells maintained only with medium were used as negative control (control). Results were analyzed by ANOVA followed by Tukey’s
multiple comparison test. Results are given as means6S.E. Note that the clonogenic growth of SK-Mel-28 cells was severely affected only in presence
of R24/Saporin-Ab (***p,0.0001, respect to control condition at 7+3 days).
doi:10.1371/journal.pone.0055304.g005
Ganglioside GD3-Targeted Immunotoxin
PLOS ONE | www.plosone.org 8 January 2013 | Volume 8 | Issue 1 | e55304
saporin translocate to the cytosolic compartment. At the cytosol,
saporin inhibits protein synthesis and induces apoptosis.
Interestingly, biotinylated R24 antibody was also effective for
targeted delivery of streptavidin-saporin, resulting in a significant
reduction of viability of GD3-expressing cells (Figure S3). This
result indicates that a simplified and safer R24-immunotoxin
complex might be used in future evaluation of its potential
therapeutic, precluding antigen competition between the saporin-
conjugated secondary antibody with immunoglobulin from the
host.
Antibody-drug conjugates are emerging as a highly effective
therapy for cancer. Recent developments have led to an increase
in the number of antibody-drug conjugates being tested clinically
[18]. From our study, the ganglioside GD3 emerges as a novel and
attractive class of cell surface molecule (glycolipid) for targeted
delivery of drugs. The reason for its attractiveness is its
accessibility, low expression on normal cells, high expression in
many tumor cells, mainly those from neuroectodermal and
epithelial origin, and mainly for its capacity to undergo
endocytosis after binding with extracellular ligands such as
antibodies.
In conclusion, results from this study point out that, in-
dependently of the endocytic pathway followed by the R24
antibody, it is possible to potentiate its cytotoxic properties on
target cells by linking it to saporin or, eventually, to other drugs
such as paclitaxel (Taxol) and doxorubicin [19,20]. We hypoth-
esize that this will aid in bypassing multiple drug resistance
mediated by the p-glycoprotein pumps. Furthermore, a synergistic
cytotoxic effect of R24 antibody-drug conjugate could be achiev-
able by combination with antineoplastic agents, as previously
reported [21]. Finally, other roles for R24 antibody could be
envisaged: it could be used to develop nanoparticles for active drug
targeting of nanomedicines, which eventually could also carrier
fluorescent molecules for imaging cancer cells.
Supporting Information
Figure S1 Analysis of the intracellular fate of R24 alone
or coupled to Saporin-Ab. CHO-K1GD3+ cells grown on
coverslips were incubated at 4uC to inhibit intracellular transport,
then with R24 antibody or R24/Saporin-Ab for 45 min at 4uC,
washed and fixed (A) or after washing the temperature was shifted
to 37uC for 30 min to allow the endocytosis, washed and fixed (B).
R24 antibody was detected by using goat anti-mouse IgG
conjugated with Alexa Fluor488 (upper panels). R24/Saporin-Ab
was detected by using rabbit anti-goat IgG conjugated with Alexa
Fluor488 (lower panels). Single confocal sections were taken every
0.8 mm parallel to the coverslip. Scale bar: 10 mm.
(TIF)
Figure S2 GD3 expression after prolonged R24-saporin-
Ab treatment. CHO-K1GD3+ cells were cultured at 37uC for
72 h in 96-well plates and treated with 20 nM monoclonal
antibody to GD3 R24 (R24) in combination with secondary
antibody (0.95 nM): goat antibody to mouse IgG (R24/anti-mouse
IgG) or saporin conjugated goat antibody to mouse IgG (R24/
Saporin-Ab). Then, cells were seed on coverslips, fixed and
incubated with R24 antibody. The primary antibody was detected
by using goat anti-mouse IgG conjugated with Alexa Fluor488.
Single confocal sections were taken every 0.8 mm parallel to the
coverslip. Scale bar: 10 mm.
(TIF)
Figure S3 Selective cytotoxicity of R24-biotin/strepta-
vidin-saporin on GD3 expressing cells. A) Different
amounts of R24 or R24-biotin (1 and 3, 0.4 mg; 2 and 4,
0.8 mg) were subjected to Western blot, stained with streptavidin
(IRDye 680) and antibody (Ab) to mouse IgG (IRDye 800) and
simultaneously detected using the Li-COR imaging system (Li-
COR Biotechnology, Lincoln, NE, USA). B) CHO-K1GD3+ and
Figure 6. Immunotoxin inhibits CHO-K1GD3+ and SK-Mel-28
cells colony formation. A) A schematical representation of the
experimental procedure used in B and C. CHO-K1GD3+(B) and SK-Mel-28
(C) cells (50–80 cells) were seed in 24-well plates previously coated with
0.5% agar in DMEM supplemented with 20% FBS. Cultures were
supplemented with 0.95 nM Saporin-Ab or 30 nM R24/0.95 nM
Saporin-Ab and maintained at 37uC in a hummed atmosphere.
Quantification of the colony area was performed every day, but only
indicated at 7 and 10 days. Cells maintained only with medium were
used as negative control (control). Results were analyzed by ANOVA
followed by Tukey’s multiple comparison test. Results are given as
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SK-Mel-28 cells grown on coverslips were incubated at 4uC to
inhibit intracellular transport, then with R24-biotin antibody for
45 min at 4uC, washed and fixed. R24-biotin was detected by
using anti-mouse IgG conjugated with Alexa Fluor488. Single
confocal sections were taken every 0.8 mm parallel to the coverslip.
The fluorescence micrographs shown are representative of three
independent experiments. Scale bar: 10 mm. C) SK-Mel-28 cells
were cultured at 37uC for 72 h in 96-well plates and treated with
or without R24-biotin in combination with antibody (Ab) to mouse
IgG (0,78 nM) or streptavidin-saporin (0,78 nM, Advance Target-
ing Systems, San Diego, CA, USA). As control (100% viability),
SK-Mel 28 cells were incubated only with culture medium. Cell
viability was determined using the colorimetric MTT metabolic
activity assay. Absorbance was measured at 595 nm using
a multiplate reader. Results were analyzed by ANOVA followed
by Tukey’s multiple comparison test. Results are three as
means6S.E. The relative cell viability (%) was expressed as
a percentage relative to the untreated control cells. Note that R24-
biotin/streptavidin-saporin complex shows selective and specific
cytotoxicity on melanoma cells (*, respect to control condition).
(TIF)
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